You are here: Home » Switch to Serdolect » Tolerability » No EPS

Switch off EPS

“Incidence of EPS of patients treated with Serdolect
were similar to those treated with placebo.” (ref. 1).

Extrapyramidal symptoms (EPS) are a common symptom of antipsychotic drug treatment and play a role in non-compliance and thus treatment outcomes. Serdolect delivers efficacy with placebo level EPS, resulting in better treatment adherence and overall outcome.

Published: 06/02/2007 Last updated: 18/05/2010

Switch to Serdolect

Literature Search

PubMed
Google Scholar

Landmark study (ref.2).

Study duration 8 weeks
No dose of Serdolect had any EPS measure above placebo level
The lowest dose of haloperidol, 4 mg per day, was associated with a significant incidence of EPS
The use of anti-EPS medication observed for Serdolect was at placebo-level

References:

1. Serdolect Product Monograph p87

2. Zimbroff et al. Am J Psychiatry 1997; 154: 782-91